Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.
See you next year in Boston
Coming Soon: Gallery of Photos from the 2014 Trans-Pacific Health Sciences Dialogue
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- Quartet raises $17M series AAnalgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated.
Quartet is developing inhibitors of GTP cyclohydrolase 1 (GCH1) or sepiapterin reductase (SPR), which modulate tetrahydrobiopterin (THB; BH4) synthesis, for chronic neuropathic pain indications. Quartet expects to have a lead candidate in preclinical development next year.
Novartis Venture Funds' Henry Skinner joined Quartet's board. Atlas made a seed investment in the biotech last year; partner Bruce Booth is its chairman.
Industry News from PharmAsia
- OncoTherapy Surges On TOPK Inhibitor PromiseShares in OncoTherapy Sciences (OTS) surged in Tokyo on Oct. 24 after the Japanese bioventure published promising early findings with a novel anticancer small molecule, OTS964.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/QWteIq4Zk6M" height="1" width="1" />
Upcoming Supporter Events
Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel